# Study to Investigate the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Idarucizumab in Chinese Healthy Male and Female Volunteers Who Had Taken Dabigatran Etexilate and Whose Plasma Concentrations of Dabigatran Were at or Close to Steady State

> **NCT03086356** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 12 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Dabigatran etexilate
- **DRUG:** Idarucizumab

## Key facts

- **NCT ID:** NCT03086356
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-10
- **Primary completion:** 2017-09-12
- **Final completion:** 2017-09-12
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2019-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03086356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03086356, "Study to Investigate the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Idarucizumab in Chinese Healthy Male and Female Volunteers Who Had Taken Dabigatran Etexilate and Whose Plasma Concentrations of Dabigatran Were at or Close to Steady State". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03086356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*